Developments in the Management of Myelofibrosis After ASH 2024 - Episode 5

Data for Navtemadlin in Relapsed/Refractory Myelofibrosis

Sangeetha Venugopal, MD, MS, discusses data from the BOREAS trial for navtemadlin in relapsed/refractory myelofibrosis.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Treatment Trends: JAK Inhibitor Selection in Myelofibrosis
    EP. 2: Challenges With Low-Dose Ruxolitinib in Myelofibrosis
    EP. 3: The Relationship Between Thrombocytopenia/Anemia on Disease Progression in Myelofibrosis
    EP. 4: PERSIST-2 Post Hoc OS Data for Pacritinib in Myelofibrosis
    Now Viewing
    EP. 5: Data for Navtemadlin in Relapsed/Refractory Myelofibrosis
    EP. 6: Other Notable Myelofibrosis Data From ASH 2024

    x